

Clinical Cancer Trials

HSE West North West / University of Galway Cancer Network



OLLSCOIL NA GAILLIMHE
UNIVERSITY OF GALWAY

Site	Health Area	Brief Title	Study Title	Recruitment Status	Study Type	Principal Investigator	For more Information please contact Researcher	Phone	For further Information cancertrial.ie	Study results available
GUH SUH	Gynaecological	XPORT-EC-042	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild- Type, Advanced or Recurrent Endometrial Carcinoma	Open to recruitment	Clinical Trial	Dr Michael Martin Sligo Dr Michael McCarthy Galway	Sligo: Margaret1.Burke@hse.ie Galway: marian.jennings@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT05611931	Results not yet available
GUH	Breast	Wavelia-	A Stage 2 Open-label, Single Site, Pilot Clinical Investigation to Assess the Detectability and Sizing of Invasive Breast Cancers, the Detectability of Benign Breast Lesions, as well as the Differentiation between Malignant and Benign Breast Lesions using the Wavelia #2 Microwave Breast Imaging System	Closed to recruitment	Clinical Trial	Professor Michael Kerin	olive.forde@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/wavelia/	Results not yet available
GUH	Breast	UCARE	Understanding Cardiac Events in Breast Cancer (UCARE)	Open to recruitment	Clinical Trial	Professor Aoife Lowery	GrainneB.McDonnell@hse.ie and olive.forde@hse.ie	091-24222	https://www.cancertrials.ie/ct-i-trials/ucare-ts	Results not yet available
GUH	Breast	TRIO 045	A Phase III, RANDOMIZED, Open-label, Multicenter Study Evaluating the Efficacy AND Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine MONotherapy in Patients with ESTROGEN RECEPTOR POSITIVE, Her2-negative EARLY Breast Cancer	Closed to recruitment	Clinical Trial	Professor Maccon Keane	alyssa.paz@hse.ie	091-24222	https://www.clinicaltrials.gov/study/NCT04961996	Results not yet available
GUH	Lung	Regeneron 3767-ONC-2011 Melanoma	A Phase 3 Trial of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma)	Open to recruitment	Clinical Trial	Professor Paul Donnellan	marian.jennings@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/r3767-onc-2011/	Results not yet available
GUH	Melanoma	Regeneron 2810-ONC-1788 Squamous Cell Carcinoma	A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patient with High-risk Cutaneous Squamous Cell Carcinoma	Open to recruitment	Clinical trial	Professor Paul Donnellan	marian.jennings@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/r2810-onc-1788/	Results not yet available

Site	Health Area	Brief Title	Study Title	Recruitment Status	Study Type	Principal Investigator	For more Information please contact Researcher	Phone	For further Information cancertrial.ie	Study results available
GUH	Melanoma	R3767-ONC-2055	A Phase 3 trial of Fianlimab (Anti Lag 3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with completely Resected High Risk Melanoma	Open to recruitment	Clinical Trial	Professor Paul Donnellan	marian.jennings@hse.ie	091-524222	https://www.cancertrials.ie/cti-trials/r3767-onc-2055/	Results not yet available
GUH	Ovary	Prima	A Phase 3, Randomised, Double-Blind, Placebo Controlled Multicentre Study Of Niraparib Maintenance Treatment In Patients With Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy	Open to recruitment	Clinical trial	Professor Paul Donnellan	paul.donnellan@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT02655016	Results not yet available
GUH	Prostate	Peace	A prospective randomised phase 3 study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer	Closed to recruitment	Clinical trial	Professor Cormac Small	emma.stone@universityofgalway.ie	091-524222		Results not yet available
GUH	Breast	Oasis-4	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms induced by adjuvant endocrine therapy, over 52 weeks in women with, or a high risk for developing hormone-receptor positive breast cancer	Closed to recruitment	Clinical trial	Professor Maccon Keane	marian.jennings@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT05587296	Results not yet available
GUH	Lung	NeoCOAS T2/D9077 C00001	Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)	Open to recruitment	Clinical Trial	Dr Silvie Blaskova	olive.forde@hse.ie and alyssa.paz@hse.ie	091-524222	https://www.clinicaltrials.gov/study/NCT05061550	Results not yet available
GUH	Myeloma	MAIA	Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy	Closed to recruitment	Clinical Trial	Professor Amjad Hayat	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT02252172	Results not yet available
GUH	Lymphoma	INC MOR 208 305 Firmmind	A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	To open soon	Clinical Trial	Professor Amjad Hayat	michelleb.hennessy@hse.ie	091-524222	https://www.cancertrials.ie/cti-trials/firmmind-incmor0208-305/	Results not yet available

Site	Health Area	Brief Title	Study Title	Recruitment Status	Study Type	Principal Investigator	For more Information please contact Researcher	Phone	For further Information cancertrial.ie	Study results available
GUH	AML	Hovon 150	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.	Open to recruitment	Clinical Trial	Professor Janusz Krawczyk	Dorota.Matczuk@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/hovon-150/	Results not yet available
GUH	Myeloma	GMI-1271-301	A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia	Closed to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://www.clinicaltrials.gov/study/NCT03616470	Results not yet available
GUH	CML	Enest Freedom	A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.	Closed to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT01784068	Results not yet available
GUH	Myeloma	MajesTEC-4	Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation	Open to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/majestec-4/	Results not yet available
GUH	Breast	EMBER-4	J2J-MC-JZLH "A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestran vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence"	To open soon	Clinical Trial	Professor Maccon Keane	GrainneB.McDonnell@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/ember-4/	Results not yet available
GUH	Telemedicine	ECANS	Joint Action on strengthening eHealth including telemedicine and telemonitoring for health care systems for cancer prevention and care - eCAN	Closed to recruitment	Clinical Investigation	Professor Aoife Lowery	Dorota.Matczuk@hse.ie	091-524222		Results not yet available

Site	Health Area	Brief Title	Study Title	Recruitment Status	Study Type	Principal Investigator	For more Information please contact Researcher	Phone	For further Information cancertrial.ie	Study results available
GUH	Myeloma	CPD Dara	Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)	Closed to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT04667663	Results not yet available
GUH	CLL	CLL17	A phase 3 multicentre, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration venetoclax plus ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)	Closed to recruitment	Clinical Trial	Professor Amjad Hayat	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT04608318	Results not yet available
GUH	Lymphoma	Chronos	A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) – CHRONOS-3	Closed to recruitment	Clinical Trial	Professor Amjad Hayat	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT02367040	Results not yet available
GUH	Myeloma	CC-220-MM-002 Excaliber	A phase 3, randomised, multicentre, open-label study comparing iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in subjects with relapsed or refractory multiple myeloma (RRMM)	Open to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/excaliber-rrmm/	Results not yet available
GUH	Flow cytometry	Sparrow	Collection and Processing of Peripheral Blood (PB) Specimens from healthy volunteers for Analytical Performance Evaluation of the BD FACSLyric™ Flow Cytometer Instrument	To open soon	Clinical Investigation	Professor Janusz Krawczyk	Shikha.Bakshi@hse.ie	091-524222		Results not yet available
GUH	Weight Loss in Cancer	CARes/ART2 7.13-100/Artelo	A phase 1/2 trial of the synthetic cannabinoid ART27.13 in patients with cancer anorexia and weight loss	Open to recruitment	Clinical Trial	Sligo: Dr Michael Martin Galway: Prof Dymna Waldron Galway	Sligo: Margaret1.Burke@hse.ie Galway: marian.jennings@hse.ie	091-524222	https://www.cancertrials.ie/ct-i-trials/cares-the-cancer-appetite-recovery-study/	Results not yet available
GUH	Breast	CAMBRIA 2	A phase 3 open label randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease	To open soon	Clinical trial	Professor Maccon Keane	alyssa.paz@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT05952557	Results not yet available

Site	Health Area	Brief Title	Study Title	Recruitment Status	Study Type	Principal Investigator	For more Information please contact Researcher	Phone	For further Information cancertrial.ie	Study results available
GUH	Myeloma	CA057-001 Successor	A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)	Open to recruitment	Clinical Trial	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT05519085	Results not yet available
GUH	Healthy volunteer	Bone Marrow Projects visicort BMR	Tissue Procurement for GMP Validation and Research	Open to recruitment	Observational with radiology or blood tests	Professor Janusz Krawczyk	michelleb.hennessy@hse.ie	091-524222		Results not yet available
GUH	Lymphoma	Beigene	Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation	Closed to recruitment	Clinical trial	Professor Amjad Hayat	michelleb.hennessy@hse.ie	091-524222	https://clinicaltrials.gov/study/NCT04002297	Results not yet available
GUH	Breast	ATNEC	Axillary Management in cT1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC)	To open soon	Clinical Investigation	Professor Aoife Lowery	GrainneB.McDonnell@hse.ie	091-524222		Results not yet available
GUH	Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancers	GLORIOSA -ENGOT-OV76	Randomized Multicenter, Open-label, Phase 3 Study of Bevacizumab With or Without Mirvetuximab Soravtansine for Patients with FRα-Positive Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancers Who Have not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab	To open soon	Clinical Trial	Dr Michael McCarthy	marian.jennings@hse.ie	091-524222		Results not yet available
GUH	Underserved population	Cancer and Disabilities	A Prospective Study to Identify the challenges faced by Irish Healthcare Professionals in the delivery of cancer services to people with intellectual disabilities	Open to recruitment	Observational	Dr Veronica McInerney	veronica.mcinerney@universit yofgalway.ie	091-524222		Results not yet available
GUH	Breast	Oral AntiCancer Treatments and telemedicine	A Review of Patients Prescribed Oral Anticancer Treatment for Advanced Breast Cancer- Is there a Role for Telemedicine	Open to recruitment	Observational	Dr Veronica McInerney	veronica.mcinerney@universit yofgalway.ie	091-524222		Results not yet available